Literature DB >> 9764058

Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics.

S R Holmer1, H W Hense, A H Danser, B Mayer, G A Riegger, H Schunkert.   

Abstract

OBJECTIVE: To examine the effect of concomitant intake of beta blockers with angiotensin converting enzyme (ACE) inhibitors, diuretics, or both on plasma renin concentrations in a population based sample (MONICA survey, Augsburg, Germany). SUBJECT AND METHODS: 728 individuals were studied, of whom 171 were treated using monotherapy (ACE inhibitor (n = 21), diuretic (n = 10), or beta blocker (n = 72)), or combination treatment (ACE inhibitor + diuretic (n = 32), ACE inhibitor + beta blocker (n = 7), diuretic + beta blocker (n = 22), ACE inhibitor + diuretic + beta blocker (n = 7)). The remaining 557 individuals were untreated. Indications for treatment were hypertension (75%), coronary artery disease with (12%) or without (3%) hypertension, or unknown (10%).
RESULTS: Mean (SEM) renin concentrations in individuals treated with an ACE inhibitor (41 (8) mU/l), a diuretic (41 (10) mU/l), or the combination of an ACE inhibitor and a diuretic (54 (10) mU/l) were raised compared with untreated individuals (17 (1) mU/l; p < 0.05 each). Monotherapy with a beta blocker, however, decreased mean renin concentrations (12 (1) mU/l; p < 0.01 v untreated). Renin concentrations in individuals taking a beta blocker with either an ACE inhibitor (21 (8) mU/l), or a diuretic (22 (4) mU/l), or with both an ACE inhibitor and a diuretic (21 (7) mU/L), were significantly lower compared with renin concentrations in groups not receiving beta blocker treatment (p < 0.05 each).
CONCLUSION: These data suggest that the upregulation of renin by treatment with ACE inhibitors, diuretics, or both can be largely prevented by concomitant beta blocker treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9764058      PMCID: PMC1728762          DOI: 10.1136/hrt.80.1.45

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  20 in total

Review 1.  Mechanisms regulating renin release.

Authors:  J O Davis; R H Freeman
Journal:  Physiol Rev       Date:  1976-01       Impact factor: 37.312

Review 2.  Controlling hypertension. A research success story.

Authors:  H P Dustan; E J Roccella; H H Garrison
Journal:  Arch Intern Med       Date:  1996-09-23

3.  Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass.

Authors:  H Schunkert; H W Hense; M Muscholl; A Luchner; S Kürzinger; A H Danser; G A Riegger
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

4.  Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity.

Authors:  F H Derkx; R J de Bruin; J M van Gool; M J van den Hoek; C C Beerendonk; F Rosmalen; P Haima; M A Schalekamp
Journal:  Clin Chem       Date:  1996-07       Impact factor: 8.327

5.  Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women.

Authors:  H Schunkert; A H Danser; H W Hense; F H Derkx; S Kürzinger; G A Riegger
Journal:  Circulation       Date:  1997-01-07       Impact factor: 29.690

6.  Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.

Authors:  M Azizi; G Chatellier; T T Guyene; D Murieta-Geoffroy; J Ménard
Journal:  Circulation       Date:  1995-08-15       Impact factor: 29.690

7.  The effect of renin and aldosterone inhibition by beta-adrenergic blockade on the response to the new diuretic azosemide.

Authors:  K Horký; I Gregorová; J Dvoráková
Journal:  Eur J Pharmacol       Date:  1981-02-19       Impact factor: 4.432

8.  Atenolol and chlorthalidone on blood pressure, heart rate, and plasma renin activity in hypertension.

Authors:  A H Teeuw; F H Leenen; G G Geyskes; P Boer
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

9.  Timolol and hydrochlorothiazide-amiloride in primary hypertension.

Authors:  R Henning; B E Karlberg; I Odar-Cederlöf; P O Andersson; L E Lins; O R Nilsson; K Tolagen
Journal:  Clin Pharmacol Ther       Date:  1980-12       Impact factor: 6.875

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

View more
  4 in total

1.  The Impact of beta blockade on the cardio-respiratory system and symptoms during exercise.

Authors:  Eldar Priel; Mustafaa Wahab; Tapas Mondal; Andy Freitag; Paul M O'Byrne; Kieran J Killian; Imran Satia
Journal:  Curr Res Physiol       Date:  2021-10-28

Review 2.  Beyond the usual strategies for blood pressure reduction: therapeutic considerations and combination therapies.

Authors:  T D Giles; G E Sander
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Nov-Dec       Impact factor: 3.738

3.  The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials.

Authors:  J J Brugts; M Bertrand; W Remme; R Ferrari; K Fox; S MacMahon; J Chalmers; M L Simoons; E Boersma
Journal:  Cardiovasc Drugs Ther       Date:  2017-08       Impact factor: 3.727

4.  Optimizing Precision of Hypertension Care to Maximize Blood Pressure Control: A Pilot Study Utilizing a Smartphone App to Incorporate Plasma Renin Activity Testing.

Authors:  Mai Mehanna; Yiqing E Chen; Yan Gong; Eileen Handberg; Brittney Roth; Jessica De Leon; Steven M Smith; Jonathan G Harrell; Rhonda M Cooper-DeHoff
Journal:  Clin Transl Sci       Date:  2020-11-30       Impact factor: 4.689

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.